Crosslinking as a treatment for infectious crystalline keratopathy

Infectious crystalline keratopathy (ICK) is a rare cornea disease, manifested by gray-and-white tree-like or needle-like stromal opacities with minimal signs of inflammation. The disease is caused by the colonization of microorganisms on the corneal stroma and their formation of biofilms, making them extremely resistant to treatment with antibiotics and to the immune response of the patient. Typically, the most important risk factor for ICK development is the presence of an immunodeficiency cornea condition with long-term topical steroid therapy, which is normally prescribed after keratoplasty. Two clinical cases of ICK are discussed in which the reduction of topical glucocorticoids and the intensive use of antibiotics did not result in positive clinical changes. Only after an accelerated crosslinking procedure (PACK-CXL), needlelike opacities disappeared in the area of microbial invasion and signs of infiltration appeared, indicating the restoration of the local immune response. This phenomenon is likely due to the destruction of the biofilm and the microbial agents themselves, which afterwards contributed to a more effective impact of the antibacterial drug. This combined treatment led to resorption of the inflammatory focus with the formation of local opacification. The effectiveness of PACK-CXL in infectious processes is explained by the effects of both riboflavin and ultraviolet radiation. No literature references on the use of cross-linking in the treatment of ICK are available. In our opinion, cross-linking in early ICK patients after keratoplasty is justified by the inability, in some cases, to completely discontinue glucocorticosteroid therapy, as this will greatly increase the chances of rejection and graft jailure. PACK-CXL can be an effective way of destroying the biofilm in the corneal stroma.

1. Gorovoy M.S., Stern G.A., Hood C.l., Allen C. Intrastromal noninflammatory bacterial colonization of a corneal graft. Arch. Ophthalmol. 1983; 101 (11): 1749–52. doi: 10.1001/archopht.1983.01040020751018

2. Meisler D.M., Langston R.H., Naab T.J., et al. Infectious crystalline keratopathy. Am. J. Ophthalmol. 1984; 97 (3): 337–43. doi: 10.1016/0002-9394(84)90633-0

3. Bowling B., Kanski J. J. Kanski’s clinical ophthalmology: a systematic approach. Edinburgh: Elsevier; 2016.

4. Mannis M.J., Holland E.J. Cornea, Surgery of the Cornea and Conjunctiva. Fourth Edition: Elsevier; 2017.

5. Kinota S., Wong K.W., Biswas J., Rao N.A. Changing patterns of infectious keratitis: overview of clinical and histopathologic features of keratitis due to acanthamoeba or atypical mycobacteria, and of infectious crystalline keratopathy. Indian J. Ophthalmol. 1993; 41 (1): 3–14.

6. Mesiwala N.K., Chu C.T., Raju L.V. Infectious crystalline keratopathy predominantly affecting the posterior cornea. Int. J. Clin. Exp. Pathol. eCollection. 2014; 7 (8): 5250–3.

7. Труфанов С.В., Шахбазян Н.П., Зайцев А.В., Розинова В.Н. Хирургические методы лечения инфекционных кератитов. Вестник офтальмологии. 2021; 137 (4): 128–35.

8. Fulcher T.P., Dart J.K., McLaughlin-Borlace L., et al. Demonstration of biofilm in infectious crystalline keratopathy using ruthenium red and electron microscopy. Ophthalmology. 2001; 108 (6): 1088–92. doi: 10.1016/s0161-6420(01)00561-9

9. Tu E.Y., Jain S. Topical linezolid 0.2 % for the treatment of vancomycinresistant or vancomycin-intolerant gram-positive bacterial keratitis. Am. J. Ophthalmol. 2013; 155 (6): 1095–8. e1. https://doi:10.1016/j.ajo.2013.01.010

10. Farooq A.V., Hou J.H., Jassim S., et al. Biofilm formation on bandage contact lenses worn by patients with the Boston type 1 keratoprosthesis: a pilot comparison study of prophylactic topical Vancomycin 15 mg/mL and Linezolid 0.2. eye contact lens. 2018; 44 (1): 106–9. doi: 10.1097/ICL.0000000000000337

11. Haas W., Pillar C.M., Torres M., Morris T.W., Sahm D.F. Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study. Am. J. Ophthalmol. 2011; 152 (4): 567–74. e3. doi: 10.1016/j.ajo.2011.03.010

12. Eiferman R.A., Forgey D.R., Cook Y.D. Excimer laser ablation of infectious crystalline keratopathy. Arch. Ophthalmol. 1992; 110 (1): 18. https://doi:10.1001/archopht.1992.01080130020011

13. Masselos K., Tsang H.H., Ooi J.L., et al. Laser corneal biofilm disruption for infectious crystalline keratopathy. Clin. Exp. Ophthalmol. 2009; 37 (2): 177–80. https://doi:10.1111/j.1442-9071.2008.01912.x

14. Sharma N., Vajpayee R.B., Pushker N., Vajpayee M. Infectious crystalline keratopathy. CLAO J. 2000; 26 (1): 40–3. PMID: 10656309

15. Touzeau O., Bourcier T., Borderie V.M., Laroche L. Recurrent infectious crystalline keratopathy caused by different organisms in two successive corneal grafts in the same patient. Br. J. Ophthalmol. 2003; 87 (8): 1053. https://doi:10.1136/bjo.87.8.1053

16. Астахов С.Ю., Новиков С.А., Папанян С.С., Рикс И.А. Оценка эффективности ускоренного коллагенового кросслинкинга в лечении эндотелиальной декомпенсации роговицы. Офтальмология. 2020; 17 (4): 699–704.